Comparison of clinical and molecular genetic criteria for diagnosing familial hypercholesterolemia

Future Lipidology

Volumn 4, Issue 3, 2009, Pages 303-310

  Leren, Trond P ^a   Berge, Knut Erik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cholesterol; Coronary heart disease; Diagnosis; Familial hypercholesterolemia; LDL receptor; Mutation; Xanthoma

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

AUTOSOMAL DOMINANT INHERITANCE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CORNEA CURVATURE; DIAGNOSTIC PROCEDURE; DNA SEQUENCE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MOLECULAR GENETICS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; XANTHOMA;

EID: 67249101550     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.24     Document Type: Review

References (50)

1. Goldstein JL, Hobbs HH, Brown MS: Familial hypercholesterolemia. In: The Metabolic Basis of Inherited Disease. Scriver CR, Baudet AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA 2863-2913 (2001).
2. Slack J: Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 2(7635), 1380-1382 (1969).
3. Scientific Steering Committee on behalf of the Simon Broome Register Group: Risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ 303, 893-896 (1991).
4. Scientific Steering Committee on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 142, 105-112 (1999).
5. Heiberg A, Berg K: The inheritance of hyperlipoproteinemia with xanthomatosis. A study of 132 kindreds. Clin. Genet. 9, 203-233 (1976).
6. Slack J: Inheritance of familial hypercholesterolemia. In: Atherosclerosis Reviews, Volume 5. Paoletti R, Gotto AM (Eds). Raven Press, NY, USA, 35-66 (1979).
7. Williams RR, Hamilton-Craig I, Kostner GM et al.: MEDPED: an integrated genetic strategy for preventing early deaths. In: Genetic Approaches to Noncommunicable Diseases. Berg K, Boulyjenkov V, Christen Y (Eds). Springer Verlag-Berlin, Berlin, Germany 35-46 (1996).
8. Huigen R, Vissers MN, Defesche JC et al.: Familial hypercholesterolemia: current treatment and advances in management. Expert Rev. Cardiovasc. 6, 567-581 (2008).
9. Wood D, De Backer G, Faergeman O et al.: Prevention of coronary heart disease in clinical prectice: recommendation of the Second Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis 140, 199-270 (1998).
10. Neil HAW, Hammond T, Matthews DR, Humphries SE: Extent of underdiagnosis of familial hypercholesterolemia in routine practice: prospective registry study. BMJ 321, 148 (2000).
11. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE: Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 11, 26-35 (2008).
12. Study Group, European Atherosclerosis Society: The recognition and management of hyperlipiemia in adults: a policy statement of the European Atherosclerosis Society. Eur. Heart J. 9, 571-600 (1988).
13. Leren TP, Tonstad S, Rødningen OK et al.: Molecular genetics of familial hypercholesterolemia in Norway. J. Int. Med. 241, 185-194 (1997).
14. Soria LF, Ludwig EH, Clarke HRG et al.: Association between a specific apolipoprotein B mutation and familial defective apoB-100. Proc. Natl Acad. Sci. USA 86, 587-591 (1989).
15. Abifadel M, Varret M, Rabes JP et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003).
16. Marks D, Wonderling D, Thorogood M et al.: Screening for hypercholesterolemia versus case finding for familial hypercholesterolaemia: systematic review and cost-effectiveness analysis. Hlth Technol. Assess. 4, 1-123 (2000).
17. Krawczak M, Cooper DN, Smidtke J: Estimating the efficacy and efficiency of cascade genetic screening. Am. J. Hum. Genet. 69, 361-370 (2001).
18. Starr B, Hadfield SG, Hutten BA et al.: Development of sensitive age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 46, 791-803 (2008).
19. Pimstone SN, Sun XM, du Souich C et al.: Phenotypic variation in heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18, 309-315 (1998).
20. Williams RR, Hunt SC, Schumacher MC et al.: Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72, 171-176 (1993).
21. Leren TP, Manshaus T, Skovholt U et al.: Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin. Vasc. Med. 4, 75-85 (2004).
22. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG et al.: Review of the first 5 years of screening for familial hypercholesterolemia in The Netherlands. Lancet 357, 165-168 (2001).
23. ten Asbroek AHA, Marang-van de Mheen PJ, Defesche JC et al.: Results from a family and DNA based active identification programme for familial hypercholesterolaemia. J. Epidemiol. Community Health 55, 500-502 (2001).
24. Familial hypercholesterolemia. In: Report of a WHO Consultation. World Health Organization, Geneva, Switzerland (1997).
25. Winder AF, Jolleys JCW, Day LB, Butowski PF: Corneal arcus, case finding and definition of individual clinical risk in heterozygous familial hypercholesterolaemia. Clin. Genet. 54, 497-502 (1998).
26. Williams RR, Hopkins PN, Hunt SC et al.: Population-based frequency of dyslipidemia syndromes in coronary prone families in Utah. Arch. Intern. Med. 150, 582-588 (1990).
27. Koivisto UM, Hamalainen L, Taskinen MR, Kettunen K, Kontula K: Prevalence of familial hypercholesterolemia among young North Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. J. Lipid Res. 34, 269-277 (1993).
28. Defesche J: Familial hypercholesterolemia. In: Lipids and Vascular Disease. Betteridge DJ (Ed.) Martin Dunitz Ltd, London, UK, 65-76 (2000).
29. Südhof TC, Goldstein JL, Brown MS, Russell DW: The LDL receptor gene: a mosaic of exons shared with different proteins. Science 228, 815-822 (1985).
30. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE: Update and analysis of the University College London low density liporpotein receptor familial hypercholesterolemia database. Ann. Hum. Genet. 72, 485-498 (2008).
31. Sanger F, Nicklen S, Coulon AR: DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 12, 5463-5467 (1977).
32. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl Acad. Sci. USA 86, 2766-2770 (1989).
33. Sheffield VC, Cox DR, Lerman LS, Myers RM: Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc. Natl Acad. Sci. USA 86, 232-236 (1989).
34. Fouchier SW, Defesche JC, Umans-Eckenhausen MAW et al.: The molecular basis of familial hypercholesterolemia in The Netherlands. Hum. Genet. 109, 602-615 (2001).
35. Heath K, Gudnason V, Humphries SE et al.: The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 143, 41-54 (1999).
36. Damgaard D, Larsen ML, Nissen PH et al.: The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 180, 155-160 (2005).
37. Wright WT, Heggarty SV, Young IS et al.: Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin. Genet. 74, 463-468 (2008)
38. Tejedor D, Castillo S, Mozas P et al.: Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin. Chem. 51, 1137-1144 (2005).
39. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98, 503-517 (1975).
40. Holla ØL, Teie C, Berge KE, Leren TP: Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA. Clin. Chim. Acta 356, 164-171 (2005).
41. Heath K, Day IN, Humphries SE: Universal primer quantitative fluorescent multiplex (UPQFM) PCR: a method to detect major and minor rearrangements of the low density lipoprotein receptor gene. J. Med. Genet. 37, 272-280 (2000).
42. Vinker S, Shani M, Baevsky T, Elhayany A: Adherence with statins over 8 years in a usual care setting. Am. J. Manag. Care 14, 388-392 (2008)
43. Briesacher BA, Andrade SE, Fouayzi H, Chan KA: Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28, 437-443 (2008).
44. Yilmaz MB, Pinar M, Naharci I et al.: Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc. Drugs Ther. 19, 437-440 (2005).
45. Wierzbicki AS, Humphries SE, Minhas R: Familial hypercholesterolaemia: summary of NICE guidance. BMJ 337, 509-511 (2008).
46. Daniels SR, Greer FR: Lipid screening and cardiovascular health in childhood. Pediatrics 122, 198-208 (2008).
47. Nicholls DP, Cather M, Byrne C, Graham CA, Young IS: Diagnosis of heterozygous familial hypercholesterolaemia in children. Int. J. Clin. Pract. 62, 990-994 (2008).
48. Umans-Eckenhausen MAW, Defesche JC, van Dam MJ et al.: Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch. Intern. Med. 163, 65-68 (2003).
49. Wilson JMG, Jungner G: Principles and practice for screening of disease. WHO, Geneva, Switzerland (1968).
50. Pocovi M, Civeira F, Alonso R, Mata P: Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin. Vasc. Med. 4, 67-74 (2004).